Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
about
An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritisPharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapiesOld and new treatment targets in axial spondyloarthritisSpanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisShould axial spondyloarthritis without radiographic changes be treated with anti-TNF agents?Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort.Is there a role for sulphasalazine in axial spondyloarthritis in the era of TNF inhibition? Data from the NOR-DMARD longitudinal observational study.Effectiveness of tumor necrosis factor α blockers in early axial spondyloarthritis: data from the DESIR cohort.Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritisThe Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.Advances in managing ankylosing spondylitisAdalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuationEvaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis.Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritisRandomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.External Validation of a Referral Rule for Axial Spondyloarthritis in Primary Care Patients with Chronic Low Back Pain.Predictive Factors of Clinical Response of Infliximab Therapy in Active Nonradiographic Axial Spondyloarthritis PatientsEffectiveness of Adalimumab in Non-radiographic Axial Spondyloarthritis: Evaluation of Clinical and Magnetic Resonance Imaging Outcomes in a Monocentric Cohort.Study protocol for a cluster randomized controlled trial to evaluate a referral strategy for axial spondyloarthritis in young primary care patients with chronic low back pain; an impact study.Clinical characteristics of Japanese patients with axial spondyloarthritis, and short-term efficacy of adalimumab.ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.A randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisThe prevalence and clinical characteristics of nonradiographic axial spondyloarthritis among patients with inflammatory back pain in rheumatology practices: a multinational, multicenter studyA psychometric analysis of outcome measures in peripheral spondyloarthritis.Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.A Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Adalimumab in Pediatric Patients With Enthesitis-Related Arthritis.A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain.Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two-Year Follow-up Period in Recent-Onset Spondyloarthritis.Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.Review: Nonradiographic axial spondyloarthritis: new definition of an old disease?Classification criteria: peripheral spondyloarthropathy and psoriatic arthritis.
P2860
Q26741170-67532C8F-82D7-48A4-A252-0F99F51108B5Q26777084-95C239E9-5D48-4C98-B3C3-8F1CF20F9162Q26777906-467393F8-81D2-4ADD-91D3-55546FF8E74DQ26852081-087535E4-4C7B-4E50-B2DB-07F9AE6DD4A6Q30239856-AAFB9BE7-B399-4DF2-912F-415F830EA9F8Q30240183-4F2F7F05-4EDC-4762-81F4-6B4D54F078A5Q30240212-2648EF4B-A9F5-4B3D-9843-5B71B510579CQ30725992-FAFD29CE-5521-4A00-998A-68AFE0A71276Q30750448-7BC55BB5-B482-4D6B-91A6-7A2215A254E0Q30776497-AAEE4025-7DE6-4C42-8550-CC7FF7848BB6Q33661893-468E90BE-8B59-47A5-9CC7-59C90278EAA5Q33710428-45ECA415-EF33-44CC-B456-E1F004677A18Q34201927-C3633A37-9DDD-4447-9603-9611C8173B88Q34669637-37D50D9E-E0EA-45ED-A6E4-D95244715893Q34808170-DFEF4113-099F-4F97-BC0E-32CFEB4B90B7Q34894874-D71EC406-5A12-4430-A20D-8B71B1C3F6E0Q34941693-2CF0DE13-D58A-45CA-9295-14BC114ED0E8Q35535807-1D4747FF-1605-45E4-B9CF-9CEFC7505851Q35705614-18B3957B-9A0B-4D5D-ACE9-7F306480F890Q35931041-1FEB66DA-0721-4928-90EA-A6B330C4B4B6Q36009390-3BB0942F-6265-47AE-813E-F09B5C3AA525Q36074193-FC215011-54D5-4BD6-9878-AD85F2C58C74Q36300483-B0C2ED66-0677-4016-83FD-E3AFF195A326Q36366162-EF100392-9905-40B5-99A6-AD36A7F3CD44Q36477447-1DAEAB09-5F1C-4BD0-A4E7-36EE364FEB73Q36584217-1EE65569-45E0-4FB7-B119-BB208CB24D41Q36976429-E1FD46C5-4BE9-4F2B-8A15-6084CC7D08A3Q37085650-9FB4ABAF-DD3D-4905-BCE1-454CD1B23389Q37228801-6C19B2A8-FB96-44C4-BEEF-B86261A1222BQ37325983-85D9C20F-0218-4182-93BC-116A0D24FAF5Q37369583-096CD789-05AE-4872-9DFA-15B4571382F0Q37391729-E5ED966B-D5A3-4337-B90F-A009BBEE5A7CQ37456359-FB2C65C4-943B-4701-9E08-E63B8FF54DE2Q37465416-36C0107B-57F4-4DB8-939B-7C9AC4AEA10CQ37465467-4E95B5E1-700F-4234-8A15-C439AA62E647Q37465472-6E7EB767-A1E5-4AA1-AE97-D4180CDCA49BQ37465518-D3305C09-CAC5-4D71-AEF5-A7EB01E4C4FEQ37690041-7E67CE16-77DA-441A-9F98-4AA91A721169Q38066807-BCCBAFE7-1474-4B4A-B431-C0C802415F39Q38084180-0069AFC9-E689-45C0-8ACC-0DB7F055237F
P2860
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and safety of adalimu ...... -controlled trial (ABILITY-1).
@en
type
label
Efficacy and safety of adalimu ...... -controlled trial (ABILITY-1).
@en
prefLabel
Efficacy and safety of adalimu ...... -controlled trial (ABILITY-1).
@en
P2093
P2860
P50
P1476
Efficacy and safety of adalimu ...... -controlled trial (ABILITY-1).
@en
P2093
Aileen L Pangan
Joachim Sieper
Philip J Mease
Vipin Arora
P2860
P304
P356
10.1136/ANNRHEUMDIS-2012-201766
P407
P577
2012-07-07T00:00:00Z